Molecular Tissue Profiling in a Clinically Selected Pancreatic Cancer Cohort
Oncology Research and Treatment · 2025
DOI: 10.1159/000543997 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research and Treatment, 2025. Verfasst von Stefanie Hegenberg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Palliative Care, St. Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Biomarkers, Tumor. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a challenging malignancy and precision oncology treatment options may improve patient outcomes. Next-generation sequencing (NGS) is an established tool that enables multigene panel analysis.
Methods
This NGS tissue-based analysis, conducted at a German pancreatic cancer center, included 128 patients between January 2016 and January 2021.
Results
A targetable lesion was detected in 15.6% of patients. BRCA1/2 mutations were identified in 16 patients, of whom 13 had germline mutations; 8 of these patients received olaparib. In 41.4% of patients, homologous recombination repair genes were affected. Two cases of ATP1B1-NRG1 fusions and seven cases of dMMR tumors were found, leading to individualized treatment. KRAS mutations were present in 70.3%, and TP53 mutations were present in 63.3%. A total of 80.5% of patients received platinum-based chemotherapy, predominantly FOLFIRINOX.
Conclusion
The high frequency of targetable alterations in our cohort underscores upfront NGS testing in PDAC. Younger patients, those with a positive family history, and KRAS WT patients should be of particular interest.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Oncology and Palliative Care, St. Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany.
- Institute of Pathology, Ruhr-University Bochum, Bochum, Germany.
Zitieren
APA
Hegenberg, S., Germing, T., Schlageter, E., Ekmekciu, I., Christmann, J., Tannapfel, A., & Reinacher-Schick, A. (2025). Molecular Tissue Profiling in a Clinically Selected Pancreatic Cancer Cohort. Oncology Research and Treatment. https://doi.org/10.1159/000543997
Vancouver
Hegenberg S, Germing T, Schlageter E, Ekmekciu I, Christmann J, Tannapfel A, et al. Molecular Tissue Profiling in a Clinically Selected Pancreatic Cancer Cohort. Oncology Research and Treatment. 2025. doi:10.1159/000543997
BibTeX
@article{Hegenberg2025,
author = {Hegenberg, Stefanie and Germing, Tobias and Schlageter, Elena and Ekmekciu, Ira and Christmann, Jens and Tannapfel, Andrea and Reinacher-Schick, Anke},
title = {Molecular Tissue Profiling in a Clinically Selected Pancreatic Cancer Cohort},
journal = {Oncology Research and Treatment},
year = {2025},
doi = {10.1159/000543997}
}
EUVIMED